Pathology - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 7 of 7
  • Item
    No Preview Available
    Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH
    Win, AK ; Reece, JC ; Dowty, JG ; Buchanan, DD ; Clendenning, M ; Rosty, C ; Southey, MC ; Young, JP ; Cleary, SP ; Kim, H ; Cotterchio, M ; Macrae, FA ; Tucker, KM ; Baron, JA ; Burnett, T ; Le Marchand, L ; Casey, G ; Haile, RW ; Newcomb, PA ; Thibodeau, SN ; Hopper, JL ; Gallinger, S ; Winship, IM ; Lindor, NM ; Jenkins, MA (WILEY, 2016-10-01)
  • Item
    Thumbnail Image
    Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre
    MacInnis, RJ ; Bickerstaffe, A ; Apicella, C ; Dite, GS ; Dowty, JG ; Aujard, K ; Phillips, K-A ; Weideman, P ; Lee, A ; Terry, MB ; Giles, GG ; Southey, MC ; Antoniou, AC ; Hopper, JL (NATURE PUBLISHING GROUP, 2013-09-03)
    BACKGROUND: Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is a risk prediction algorithm that can be used to compute estimates of age-specific risk of breast cancer. It is uncertain whether BOADICEA performs adequately for populations outside the United Kingdom. METHODS: Using a batch mode version of BOADICEA that we developed (BOADICEACentre), we calculated the cumulative 10-year invasive breast cancer risk for 4176 Australian women of European ancestry unaffected at baseline from 1601 case and control families in the Australian Breast Cancer Family Registry. Based on 115 incident breast cancers, we investigated calibration, discrimination (using receiver-operating characteristic (ROC) curves) and accuracy at the individual level. RESULTS: The ratio of expected to observed number of breast cancers was 0.92 (95% confidence interval (CI) 0.76-1.10). The E/O ratios by subgroups of the participant's relationship to the index case and by the reported number of affected relatives ranged between 0.83 and 0.98 and all 95% CIs included 1.00. The area under the ROC curve was 0.70 (95% CI 0.66-0.75) and there was no evidence of systematic under- or over-dispersion (P=0.2). CONCLUSION: BOADICEA is well calibrated for Australian women, and had good discrimination and accuracy at the individual level.
  • Item
    Thumbnail Image
    Population-Based Estimate of Prostate Cancer Risk for Carriers of the HOXB13 Missense Mutation G84E
    MacInnis, RJ ; Severi, G ; Baglietto, L ; Dowty, JG ; Jenkins, MA ; Southey, MC ; Hopper, JL ; Giles, GG ; Peterlongo, P (PUBLIC LIBRARY SCIENCE, 2013-02-15)
    The HOXB13 missense mutation G84E (rs138213197) is associated with increased risk of prostate cancer, but the current estimate of increased risk has a wide confidence interval (width of 95% confidence interval (CI) >200-fold) so the point estimate of 20-fold increased risk could be misleading. Population-based family studies can be more informative for estimating risks for rare variants, therefore, we screened for mutations in an Australian population-based series of early-onset prostate cancer cases (probands). We found that 19 of 1,384 (1.4%) probands carried the missense mutation, and of these, six (32%) had a family history of prostate cancer. We tested the 22 relatives of carriers diagnosed from 1998 to 2008 for whom we had a DNA sample, and found seven more carriers and one obligate carrier. The age-specific incidence for carriers was estimated to be, on average, 16.4 (95% CI 2.5-107.2) times that for the population over the time frame when the relatives were at risk prior to baseline. We then estimated the age and birth year- specific cumulative risk of prostate cancer (penetrance) for carriers. For example, the penetrance for an unaffected male carrier born in 1950 was 19% (95% CI 5-46%) at age 60 years, 44% (95% CI 18-74%) at age 70 years and 60% (95% CI 30-85%) at age 80 years. Our study has provided a population-based estimate of the average risk of prostate cancer for HOXB13 missense mutation G84E carriers that can be used to guide clinical practice and research. This study has also shown that the majority of hereditary prostate cancers due to the HOXB13 missense mutation are 'sporadic' in the sense that unselected cases with the missense mutation do not typically report having a family history of prostate cancer.
  • Item
    No Preview Available
    Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives
    Win, AK ; Buchanan, DD ; Rosty, C ; MacInnis, RJ ; Dowty, JG ; Dite, GS ; Giles, GG ; Southey, MC ; Young, JP ; Clendenning, M ; Walsh, MD ; Walters, RJ ; Boussioutas, A ; Smyrk, TC ; Thibodeau, SN ; Baron, JA ; Potter, JD ; Newcomb, PA ; Le Marchand, L ; Haile, RW ; Gallinger, S ; Lindor, NM ; Hopper, JL ; Ahnen, DJ ; Jenkins, MA (BMJ PUBLISHING GROUP, 2015-01)
    OBJECTIVE: To estimate risk of colorectal cancer (CRC) for first-degree relatives of CRC cases based on CRC molecular subtypes and tumour pathology features. DESIGN: We studied a cohort of 33,496 first-degree relatives of 4853 incident invasive CRC cases (probands) who were recruited to the Colon Cancer Family Registry through population cancer registries in the USA, Canada and Australia. We categorised the first-degree relatives into four groups: 28,156 of 4095 mismatch repair (MMR)-proficient probands, 2302 of 301 MMR-deficient non-Lynch syndrome probands, 1799 of 271 suspected Lynch syndrome probands and 1239 of 186 Lynch syndrome probands. We compared CRC risk for first-degree relatives stratified by the absence or presence of specific tumour molecular pathology features in probands across each of these four groups and for all groups combined. RESULTS: Compared with first-degree relatives of MMR-proficient CRC cases, a higher risk of CRC was estimated for first-degree relatives of CRC cases with suspected Lynch syndrome (HR 2.06, 95% CI 1.59 to 2.67) and with Lynch syndrome (HR 5.37, 95% CI 4.16 to 6.94), but not with MMR-deficient non-Lynch syndrome (HR 1.04, 95% CI 0.82 to 1.31). A greater risk of CRC was estimated for first-degree relatives if CRC cases were diagnosed before age 50 years, had proximal colon cancer or if their tumours had any of the following: expanding tumour margin, peritumoral lymphocytes, tumour-infiltrating lymphocytes or synchronous CRC. CONCLUSIONS: Molecular pathology features are potentially useful to refine screening recommendations for first-degree relatives of CRC cases and to identify which cases are more likely to be caused by genetic or other familial factors.
  • Item
    Thumbnail Image
    Tumour morphology predicts PALB2 germline mutation status
    Teo, ZL ; Provenzano, E ; Dite, GS ; Park, DJ ; Apicella, C ; Sawyer, SD ; James, PA ; Mitchell, G ; Trainer, AH ; Lindeman, GJ ; Shackleton, K ; Cicciarelli, L ; Buys, SS ; Andrulis, IL ; Mulligan, AM ; Glendon, G ; John, EM ; Terry, MB ; Daly, M ; Odefrey, FA ; Nguyen-Dumont, T ; Giles, GG ; Dowty, JG ; Winship, I ; Goldgar, DE ; Hopper, JL ; Southey, MC (NATURE PUBLISHING GROUP, 2013-07-09)
    BACKGROUND: Population-based studies of breast cancer have estimated that at least some PALB2 mutations are associated with high breast cancer risk. For women carrying PALB2 mutations, knowing their carrier status could be useful in directing them towards effective cancer risk management and therapeutic strategies. We sought to determine whether morphological features of breast tumours can predict PALB2 germline mutation status. METHODS: Systematic pathology review was conducted on breast tumours from 28 female carriers of PALB2 mutations (non-carriers of other known high-risk mutations, recruited through various resources with varying ascertainment) and on breast tumours from a population-based sample of 828 Australian women diagnosed before the age of 60 years (which included 40 BRCA1 and 18 BRCA2 mutation carriers). Tumour morphological features of the 28 PALB2 mutation carriers were compared with those of 770 women without high-risk mutations. RESULTS: Tumours arising in PALB2 mutation carriers were associated with minimal sclerosis (odds ratio (OR)=19.7; 95% confidence interval (CI)=6.0-64.6; P=5 × 10(-7)). Minimal sclerosis was also a feature that distinguished PALB2 mutation carriers from BRCA1 (P=0.05) and BRCA2 (P=0.04) mutation carriers. CONCLUSION: This study identified minimal sclerosis to be a predictor of germline PALB2 mutation status. Morphological review can therefore facilitate the identification of women most likely to carry mutations in PALB2.
  • Item
    No Preview Available
    Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families
    Teo, ZL ; Park, DJ ; Provenzano, E ; Chatfield, ; Odefrey, FA ; Nguyen-Dumont, ; KConFab, ; Dowty, JG ; Hopper, JL ; Winship, IM ; Goldgar, E ; Southey, MC ( 2013)
  • Item
    Thumbnail Image
    Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families
    Teo, Z ; PARK, DANIEL ; Provenzano, E ; CHATFIELD, CATHERINE ; Odefrey, F ; Nguyen-Dumont, T ; K, kConFab ; DOWTY, JAMES ; HOPPER, JOHN ; WINSHIP, INGRID ; Goldgar, D ; SOUTHEY, MELISSA ( 2013)